When Does Mavyret's Exclusivity End?
Mavyret, an antiviral medication developed by AbbVie for the treatment of hepatitis C, is approaching the end of its market exclusivity. The exact date of loss of exclusivity can be complex, often involving multiple patents and potential legal challenges.
What is the Key Patent Expiration Date for Mavyret?
The primary patent protecting Mavyret's active pharmaceutical ingredients and their use is U.S. Patent No. 9,241,988. This patent is currently set to expire on November 22, 2027 [1]. However, other patents related to Mavyret's formulation and manufacturing processes may have different expiration dates. Information on all relevant patents can be found on DrugPatentWatch.com [1].
Can Generic Versions of Mavyret Be Available Before Patent Expiry?
The entry of generic versions of Mavyret before the expiration of key patents typically depends on several factors. These include the strength of the patents, any Orange Book listings, and potential patent litigation. Companies often file Abbreviated New Drug Applications (ANDAs) for generic versions, and the Food and Drug Administration (FDA) will only approve these if they do not infringe on existing patents. Successful patent challenges or settlements can also lead to earlier generic availability [1].
What Happens When Mavyret Loses Exclusivity?
Upon loss of exclusivity, the market for Mavyret will likely open to generic competitors. This typically leads to a significant decrease in the price of the medication as generic manufacturers offer their versions at a lower cost. Patients may then have access to more affordable treatment options, and healthcare systems can see reduced overall spending on this therapy.
How Does Mavyret Compare to Other Hepatitis C Treatments?
Mavyret is a pan-genotypic treatment, meaning it is effective against all genotypes of the hepatitis C virus. It is a combination therapy consisting of glecaprevir and pibrentasvir and is known for its relatively short treatment duration, often as little as eight weeks for most patients [2]. Other hepatitis C treatments include direct-acting antivirals (DAAs) with varying drug combinations and efficacy profiles against different genotypes, such as sofosbuvir/ledipasvir and sofosbuvir/velpatasvir [3].
Who Holds the Patents for Mavyret?
The patents for Mavyret are held by AbbVie Inc. and its subsidiaries [1]. AbbVie is the originator company that developed and currently markets the drug.
What is the Impact on Patients When Generics Become Available?
The availability of generic Mavyret is expected to increase patient access to treatment due to lower costs. Patients may be able to switch to generic versions, potentially reducing their out-of-pocket expenses. However, they should consult with their healthcare providers to ensure the generic is an appropriate substitute for their specific needs.
---
Sources:
1. DrugPatentWatch.com. https://www.drugpatentwatch.com/
2. Mavyret Prescribing Information. (Details on specific prescribing information not provided in source material, but Mavyret's efficacy and duration are generally known public information).
3. National Institute of Diabetes and Digestive and Kidney Diseases. Hepatitis C: Overview. (Details on specific NIDDK information not provided in source material, but general knowledge of DAAs is publicly available).